Patients with diabetes and chronic kidney disease receiving physiologic insulin resensitization had much lower annual costs of care than similar patients not receiving it.
Roy H. Hinman II, MD
Advertisement
Articles by Roy H. Hinman II, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
2
New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor
3
How Often Do Health Insurers Deny Doctor-Recommended Care?
4
Sudden Death in HFpEF Often Preceded by Clinical Decline
5